Literature DB >> 15869721

What's new in the field of prostate cancer chemoprevention?

Kanwaljit Mahal1, Javier Hernandez, Joseph W Basler, Ian M Thompson.   

Abstract

Chemoprevention trials for several malignancies are completed, planned, or underway. Prostate cancer is one of the most common forms of cancer and understandably has received considerable recent attention as a potential target for chemoprevention. This article examines chemoprevention trials for prostate cancer, including the Prostate Cancer Prevention Trial, Selenium and Vitamin E Cancer Prevention Trial, and cyclooxygenase inhibitors in the prevention of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15869721     DOI： 10.1007/s11934-005-0005-6

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  49 in total

1.  Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US.

Authors:  Laurel A Habel; Wei Zhao; Janet L Stanford
Journal:  Cancer Causes Control       Date:  2002-06       Impact factor: 2.506

2.  Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells.

Authors:  Alexander V Gasparian; Ya Juan Yao; Junxuan Lü; Alexander Y Yemelyanov; Lyudmila A Lyakh; Thomas J Slaga; Irina V Budunova
Journal:  Mol Cancer Ther       Date:  2002-10       Impact factor: 6.261

3.  Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells.

Authors:  Yu Zhang; Jing Ni; Edward M Messing; Eugene Chang; Chin-Rang Yang; Shuyuan Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

4.  Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines.

Authors:  Vasundara Venkateswaran; Laurence H Klotz; Neil E Fleshner
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

Review 5.  Treating dyslipidemia with statins: the risk-benefit profile.

Authors:  Luther T Clark
Journal:  Am Heart J       Date:  2003-03       Impact factor: 4.749

6.  Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer.

Authors:  K Yoshizawa; W C Willett; S J Morris; M J Stampfer; D Spiegelman; E B Rimm; E Giovannucci
Journal:  J Natl Cancer Inst       Date:  1998-08-19       Impact factor: 13.506

7.  Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency.

Authors:  J Imperato-McGinley; T Gautier; K Zirinsky; T Hom; O Palomo; E Stein; E D Vaughan; J A Markisz; E Ramirez de Arellano; E Kazam
Journal:  J Clin Endocrinol Metab       Date:  1992-10       Impact factor: 5.958

8.  Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.

Authors:  Jun Luo; Thomas A Dunn; Charles M Ewing; Patrick C Walsh; William B Isaacs
Journal:  Prostate       Date:  2003-10-01       Impact factor: 4.104

Review 9.  Aspirin in the prophylaxis of coronary artery disease.

Authors:  Paulette Mehta
Journal:  Curr Opin Cardiol       Date:  2002-09       Impact factor: 2.161

10.  Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk.

Authors:  J Irani; V Ravery; J L Pariente; E Chartier-Kastler; E Lechevallier; M Soulie; D Chautard; P Coloby; E Fontaine; F Bladou; F Desgrandchamps; O Haillot
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.